Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I0YS
|
|||
| Former ID |
DIB015017
|
|||
| Drug Name |
TTP-4000
|
|||
| Synonyms |
Extracellular RAGE domain (diabetic nephropathy), TransTech; Extracellular RAGE domain (Alzheimer's disease), TransTech
Click to Show/Hide
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
| Company |
Transtech pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Advanced glycosylation end product receptor (AGER) | Target Info | Inhibitor | [2] |
| Pathway Interaction Database | amb2 Integrin signaling | |||
| Reactome | RIP-mediated NFkB activation via ZBP1 | |||
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | ||||
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | ||||
| Advanced glycosylation endproduct receptor signaling | ||||
| TRAF6 mediated NF-kB activation | ||||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Cytosolic sensors of pathogen-associated DNA | ||||
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | ||||
| AGE/RAGE pathway | ||||
| RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | ||||
| Advanced glycosylation endproduct receptor signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01548430) A Safety Study of TTP4000 in Subjects With Alzheimer's Disease. U.S. National Institutes of Health. | |||
| REF 2 | Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol. 2009; 4(2): 167-177. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.